case_images: PMC10731252_01
case_images: Map of the patient's course, duration of treatment and changes in immunoglobulins and complement during treatment. (A) Map of the patient's course. The coordinate axis shows the significant milestones from the onset of the patient's illness to the current follow-up (unit: months), including the onset of the illness, diagnosis, treatment at our hospital, and follow-ups at 1 month, 3 months, and 7 months. The hospitalization for treatment was from February 1, 2023, to February 8, 2023. (B) Treatment duration. The arrows indicate the medications used during the patient's treatment and the duration of use. Pyridostigmine bromide treatment started from the diagnosis of myasthenia gravis (January 1, 2023, to present). Corticosteroid therapy was from hospital admission until the end of May (February 1, 2023, to late May 2023). Immunoglobulin therapy was used during the hospitalization period, lasting 5 days (February 2, 2023, to February 6, 2023). Telitacicept therapy began after the stabilization of the acute phase and continues to present (February 8, 2023, to present). (C) Changes in immunoglobulins and complement during the treatment. The line graph shows changes in some data during the patient's treatment, including changes in immunoglobulin, complement, QMG, and AChR-Ab. Among these, IgG, IgA, IgM, C3, and C4 are on the left vertical axis. The unit for IgG is 10g/L. The units for IgA, IgM, C3, and C4 are g/L. QMG and AChR-Ab are on the right vertical axis. The unit for AChR-Ab is nmol/L. Note: Laboratory Reference Range for Indicators: IgG: 7.51-15.6 g/L; IgA: 0.82-4.53 g/L; IgM: 0.46-3.04 g/L; C3: 0.79-1.52 g/L; C4: 0.16-0.38 g/L; AChR-Ab: positive >0.4 nmol/L, gray area 0.25-0.40 nmol/L, negative<0.25 nmol/L.
case_images: fimmu-14-1270011-g001.jpg
case_images: PMC10731252_01_fimmu-14-1270011-g001.jpg
case_images: f1
case_images: Throughout the follow-up period, her clinical condition remained stable, her serum immunoglobulin showed a downward trend (as depicted in  Figure 1 ).